Drug Profile
Orelabrutinib - InnoCare Pharma
Alternative Names: BIIB-135; ICP 022; INNOBRUKA; YINUOKAILatest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator InnoCare Pharma
- Class Amides; Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Phenyl ethers; Piperidines; Pyridines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Preregistration Waldenstrom's macroglobulinaemia
- Phase III Diffuse large B cell lymphoma; Idiopathic thrombocytopenic purpura
- Phase II Lymphoma; Multiple sclerosis; Neuromyelitis optica; Non-Hodgkin's lymphoma; Systemic lupus erythematosus
- Phase I/II B-cell lymphoma; Follicular lymphoma
- Phase I Liver disorders
- Discontinued Rheumatoid arthritis
Most Recent Events
- 19 Dec 2023 Phase-III clinical trials in Marginal zone B-cell lymphoma (Combination therapy, Second-line therapy or greater) in China (PO) (NCT06082102)
- 09 Dec 2023 Efficacy and adverse event data from a phase II trial in Waldenstrom's macroglobulinaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 26 Oct 2023 Phase-III clinical trials in Idiopathic thrombocytopenic purpura (In the elderly, In adults) in China (PO) (InnoCare Pharma pipeline, December 2023) (NCT06004856)